|
Bev
see if your friend can have her slides sent to MD Anderson for a second pathologic opinion. They look for EGFR1 in triple negatives, making treatment with IRESSA/TARCEVA/ ERBITUX / and perhaps Tykerb in a clinical trial. In a minute I will add the latest article I found on triple negative breast cancer --just published a few days ago. It is somewhat difficult as they have fewer targets identified for treatment, although they respond better to chemotherapy than ER+ breast cancer.
Am currently packing to leave Denmark on Tuesday. If you repost your question to me a week from Sunday(allowing me time to recover somewhat from jetlag), I will be happy to do a more extensive search of the literature. I will also go through my email sent to the husband of a triple negative bc patient and forward the pertinent ones via this website to you.
Off to retrieve the recent article PS it is also referred to as basal-type breast cancer.
|